James E. Krook

19.0k total citations · 5 hit papers
136 papers, 14.6k citations indexed

About

James E. Krook is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, James E. Krook has authored 136 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in James E. Krook's work include Cancer Treatment and Pharmacology (38 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (27 papers). James E. Krook is often cited by papers focused on Cancer Treatment and Pharmacology (38 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (27 papers). James E. Krook collaborates with scholars based in United States, Canada and Switzerland. James E. Krook's co-authors include David H. Johnson, Corey J. Langer, David Harrington, Junming Zhu, Joan H. Schiller, Chandra P. Belani, Alan Sandler, Harry S. Wieand, J A Mailliard and C G Moertel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

James E. Krook

134 papers receiving 14.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 4.1k citations James E. Krook et al. profile →
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma

1991 1.4k citations James E. Krook, C G Moertel et al. profile →
Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery

1994 820 citations Harry S. Wieand, James E. Krook et al. profile →
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

1989 725 citations Michael A. Poon, C G Moertel et al. Journal of Clinical Oncology profile →
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

1989 526 citations John A. Laurie, C G Moertel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by James E. Krook

Since Specialization

Citations

This map shows the geographic impact of James E. Krook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Krook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Krook more than expected).

Fields of papers citing papers by James E. Krook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Krook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Krook. The network helps show where James E. Krook may publish in the future.

Co-authorship network of co-authors of James E. Krook

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Krook. A scholar is included among the top collaborators of James E. Krook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Krook. James E. Krook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer 2005 ·American Journal of Clinical Oncology ·Patrick A. Burch, James A. Mailliard, David W. Hillman, Edith A. Perez, James E. Krook, Kendrith M. Rowland, Michael H. Veeder, Michael W. Cannon, James N. Ingle	28
2	Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252 2005 ·Clinical Breast Cancer ·Edith A. Perez, Vera J. Suman, Kendrith M. Rowland, James N. Ingle, Muhammad Salim, Charles L. Loprinzi, Patrick J. Flynn, James A. Mailliard, Carl G. Kardinal, James E. Krook, (unknown), Daniel W. Visscher, Robert B. Jenkins	99
3	2003 ·American Journal of Clinical Oncology ·Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, (unknown), James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, (unknown)	6
4	A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer 2003 ·American Journal of Clinical Oncology ·Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, (unknown), James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, (unknown)	31
5	Randomized, Placebo-Controlled, Phase III Surgical Adjuvant Clinical Trial of Megestrol Acetate (Megace) in Selected Patients With Malignant Melanoma 2002 ·American Journal of Clinical Oncology ·Svetomir N. Markovic, Vera J. Suman, Robert J. Dalton, John E. Woods, Robert W. Beart, Lester E. Wold, Jan C. Buckner, John W. Kugler, James A. Mailliard, Kendrith M. Rowland, James E. Krook, David W. Brown, Maria Tria Tirona, Edward T. Creagan	9
6	Megestrol and Tamoxifen in Patients With Advanced Endometrial Cancer 2001 ·American Journal of Clinical Oncology ·Kishan J. Pandya, B.Y. Yeap, Louis M. Weiner, James E. Krook, John K. Erban, Roger Schinella, Thomas E. Davis	44
7	A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma 2000 ·Cancer ·Edith A. Perez, David W. Hillman, Philip J. Stella, James E. Krook, Lynn C. Hartmann, Tom R. Fitch, Alan K. Hatfield, James A. Mailliard, Suresh Nair, Carl G. Kardinal, James N. Ingle	13
8	North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy 1999 ·American Journal of Clinical Oncology ·Patrick A. Burch, (unknown), Georgene Schroeder, Joseph Rubin, James E. Krook, Robert J. Dalton, James B. Gerstner, (unknown), Larry P. Ebbert	3
9	Combined Levamisole With Recombinant Interleukin-2 (IL-2) in Patients With Advanced Renal Cell Carcinoma 1998 ·American Journal of Clinical Oncology ·Edward T. Creagan, (unknown), Vera J. Suman, (unknown), Suresh Nair, James E. Krook, John W. Kugler, Robert F. Marschke, John C. Michalak, Loren K. Tschetter	8
10	The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy 1997 ·Annals of Oncology ·Joseph L. Pater, W. Lofters, Benny Zee, E. Dempsey, David Walde, (unknown), K Wilson, Paul Hoskins, R. Guévin, Savita Verma, Rudolph M. Navari, James E. Krook, John D. Hainsworth, Michael Palmer, Christine Chin	54
11	Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma 1997 ·Journal of Neuro-Oncology ·Thomas E. Elliott, Robert P. Dinapoli, Judith R. OʼFallon, James E. Krook, John D. Earle, Roscoe F. Morton, Ralph Levitt, Loren K. Tschetter, Bernd W. Scheithauer, Delano M. Pfeifle, Donald I. Twito, Robert A. Nelimark	22
12	A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer 1996 ·JNCI Journal of the National Cancer Institute ·R.D. Gelber, Aron Goldhirsch, Bernard F. Cole, Harry S. Wieand, Georgene Schroeder, James E. Krook	95
13	Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. 1994 ·Journal of Clinical Oncology ·James R. Jett, Andrew W. Maksymiuk, John Q. Su, J A Mailliard, James E. Krook, Loren K. Tschetter, Carl G. Kardinal, Donald I. Twito, Ralph Levitt, James B. Gerstner	95
14	Measurable or assessable disease in lung cancer trials: does it matter? 1994 ·Journal of Clinical Oncology ·James R. Jett, John Q. Su, James E. Krook, Robert M. Goldberg, J. W. Kugler	15
15	Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. 1994 ·Journal of Clinical Oncology ·Stephen A. Cullinan, C G Moertel, Harry S. Wieand, M J O'Connell, Michael A. Poon, James E. Krook, J A Mailliard, Loren K. Tschetter	114
16	Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis 1991 ·Cancer ·James N. Ingle, Harry J. Long, Donald I. Twito, Daniel J. Schaid, Stephen A. Cullinan, (unknown), James E. Krook, James A. Mailliard, Loren K. Tschetter, (unknown), Ralph Levitt, Delano M. Pfeifle	91
17	Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer 1989 ·American Journal of Clinical Oncology ·James N. Ingle, J A Mailliard, Daniel J. Schaid, James E. Krook, James B. Gerstner, (unknown), Robert F. Marschke, Hui Long, G McCormack, John Foley	14
18	Alternating Chemotherapy With or Without VP-16 in Extensive-Stage Small-Cell Lung Cancer 1989 ·American Journal of Clinical Oncology ·Lloyd K. Everson, James R. Jett, Judith R. OʼFallon, James E. Krook, Robert J. Dalton, James A. Mailliard, Loren K. Tschetter, Stephen A. Cullinan, James B. Gerstner, Roscoe F. Morton, John A. Laurie	8
19	Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. 1988 ·Journal of Clinical Oncology ·James N. Ingle, Lloyd K. Everson, Harry S. Wieand, J. Kirk Martin, (unknown), Lester E. Wold, James E. Krook, Stephen A. Cullinan, (unknown), Donald I. Twito	35
20	Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma 1987 ·Gynecologic Oncology ·J H Edmonson, James E. Krook, (unknown), George D. Malkasian, Lloyd K. Everson, John A. Jefferies, J A Mailliard	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact